Drug Profile
Research programme: G protein-coupled receptor antagonists - Pfizer/Boehringer Ingelheim
Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Arena Pharmaceuticals
- Developer Boehringer Ingelheim; Pfizer
- Class Neuroprotectants; Small molecules
- Mechanism of Action G protein-coupled receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders; Schizophrenia
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in CNS-disorders in Germany
- 28 Jan 2023 No recent reports of development identified for preclinical development in CNS-disorders in USA
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer